FINWIRES · TerminalLIVE
FINWIRES

UBSは、シェブロンの第1四半期決算が年後半の「大幅な成長加速」の足がかりになると述べている。

By

-- UBSのアナリストは月曜日のレポートで、シェブロン(CVX)の第1四半期決算は、四半期ごとの収益の大幅な加速を示しており、その勢いは今年後半から2027年上半期にかけてさらに強まるだろうと述べた。 UBSは、シェブロンの第1四半期決算は、時期的な影響による大きな逆風に直面したにもかかわらず、予想を上回ったと指摘した。 アナリストは、中東紛争はシェブロンの資産に直接的な影響を与えておらず、予防措置として停止されていたプロジェクトは現在再開されていると述べた。 UBSは、第2四半期と第3四半期には、いくつかの潜在的な要因がシェブロンの収益を押し上げる可能性があると指摘した。その一つが、発表された生産能力を上回る稼働率で稼働しているTCOカザフスタン・プロジェクトであり、カザフスタン/ユーラシア地域からの生産量は第2四半期に60%増加すると見込まれている。 アナリストらは、長期契約量に関して、ブレント原油と日本産原油の混合価格が1バレルあたり10ドル上昇するごとに、税引前利益が6億ドル、税引後利益が4億5000万ドル増加すると述べている。 UBSは同社株の買い推奨を維持し、目標株価を218ドルから220ドルに引き上げた。

Price: $191.83, Change: $+1.20, Percent Change: +0.63%

Related Articles

Sectors

Update: Gold Falls as the Dollar and Yields Climb

(Updates prices.)Gold traded lower midafternoon Monday as the dollar and yields rose, forcing the precious metal below the tight range it has stuck within for the past month.Gold for June delivery was last seen down US$112.20 to US$4,533.20 per ounce, the lowest since March 27.The war on Iran has prompted some safe-haven demand for the metal, even as the higher oil prices that followed the start of the war on Iran is hiking inflation. This is raising concerns higher interest rates are on the way, which is bearish for the metal since it pays no interest."Gold remains supported by safe-haven demand as investors continue to watch the Middle East conflict, oil prices, and the yen. Any durable easing in the Strait of Hormuz would likely cool demand for defensive assets, but until shipping flows normalise, gold should remain sensitive to geopolitical headlines and shifts in real yields," Saxo Bank noted.The dollar rose, with the ICE dollar index last seen up 0.2.9 points to 98.45. Treasury yields were sharply higher, with the U.S. two-year note last seen paying 3.975%, up 8.3 basis points, while the yield on the 10-year note as up 7.0 points to 4.449%

$GCM6$GLD
Australia

Top Midday Gainers

Celcuity (CELC) reported late Friday positive topline results from a cohort of its phase 3 Viktoria-1 trial, with the study meeting its primary endpoint and showing a clinically meaningful improvement in progression-free survival.The study evaluated gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer who had progressed after a CDK4/6 inhibitor and an aromatase inhibitor.Shares jumped more than 16%, with intraday trading volume at over 2.5 million from a daily average of roughly 737,000.CNS Pharmaceuticals (CNSP) shares surged 268% amid heavy trading after the company said Monday it signed deals for a private placement financing likely to generate roughly $22.5 million.Intraday trading volume catapulted to over 78.4 million shares from a daily average of about 32,000.American Express Global Business Travel, which is operated by Global Business Travel Group (GBTG), said Monday it has entered into a definitive agreement to be acquired by Long Lake Management for $9.50 per share in an all-cash deal valued at about $6.3 billion.Shares soared 57%, with intraday trading volume of over 61.6 million from a daily average of about 1.6 million.Price: $146.00, Change: $+20.35, Percent Change: +16.20%

$CELC$CNSP$GBTG
Sectors

Sector Update: Health Care Stocks Softer in Afternoon Trading

Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.3%.The iShares Biotechnology ETF (IBB) rose 1.3%.In corporate news, Amgen (AMGN) said Monday it will invest an additional $300 million in its biologics manufacturing facility in Puerto Rico. Amgen shares were down 2.1%.Vanda Pharmaceuticals (VNDA) shares jumped past 5% after it said Monday its motion sickness drug Nereus is now commercially available in the US.Eli Lilly (LLY) shares added 0.2% after Barclays lifted the company's price target to $1,400 from $1,350, while keeping its overweight rating.Moderna (MRNA) is showing continued advancement across its pipeline, with progress in cancer vaccines and infectious disease programs supporting a more balanced risk-reward profile, RBC Capital Markets said in a note. RBC maintained its sector perform rating on the stock and raised its price target to $38 from $35. Moderna shares rose 4.6%.

$AMGN$LLY$MRNA$VNDA